QUANTITATIVE Flashcards

1
Q

Aspirin and NSAIDs - Aspirin

A

acetylate the cyclooxygenase enzyme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

add one compound to the enzyme making it non functional

A

acetylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Cyclooxygenase enzyme secretes

A

Thromboxane and Prostaglandin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CoX 2 inhibitor

A

Naproxen and Ibuprofen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Ticlopidine and Clopidogrel

A

Antiplatelet medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

prevent blood clots inside the blood vessel by preventing plt aggregation

A

Antiplatelet medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

prevent blood clots inside the blood vessel by preventing plt aggregation

A

Antiplatelet medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

administered to enhance fibrinolysis

A

Dextran

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SIGNIFICANT PLT COUNT AND INTERPRETATION

A

Significant plt levels (plt count and clinical manifestation) ● <100,000/ul - abnormally low
● 30,000-50,000/ul- bleeding possible
● <30,000- spontaneous bleeding
● <5,000/ul- severe spontaneous bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Thrombocytopenia

A

possible bleeding anytime for the patient
● Decreased in circulating platelet
● Less than 100,000/uL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Thrombocytosis

A

significant with other manifestations
● Hall Mark for myeloproliferative diseases
● Increase in circulating plt
● More than 450,000/uL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

THROMBOCYTOPENIA

A
  1. Decrease production
  2. Blood transfusion
  3. Increased destruction/consumption
  4. Splenic sequestration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
  • Large platelet, dohle like bodies (20 um)
  • Mutation in MYH9 gene: encodes for the myosin heavy chain: which affects plt activation
A

MAY HEGGLIN ANOMALY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
  • Large platelet, dohle like bodies (20 um)
  • Mutation in MYH9 gene: encodes for the myosin heavy chain: which affects plt activation
A

MAY HEGGLIN ANOMALY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
  • Absence/ hypoplasia in radial bones
A

TAR SYNDROME

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
  • Bone and visceral organ abnormalities
  • pancytopenia
  • Neonates
A

FANCONI ANEMIA

17
Q
  • Small platelets
  • Absence of megakaryocytes
    (chlorthiazide, tolbutamide)
  • directly affect the fetal BM megakaryocyte
  • 72 hours of birth : mothers pregnancy or baby’s delivery was exposed to TORCH infection
  • TORCH- Toxoplasma Rubella CMV HIV-HERPES
  • There is a case that the megakaryocyte is absent
A

NEONATAL THROMBOCYTOPENIA

18
Q

Low plt

A

BSS

19
Q
  • Dense granules
  • Small plt
A

WISKOTT ALDRICH

20
Q

for HIV treatment

A

Zidovudine

21
Q

treatment for thrombocytosis:

A

Anagrelide

22
Q

long term consumption of ethanol will be subjected to thrombocytopenia.

A

Ethanol

23
Q

restoring plts due to chemotherapy to stimulate BM to reproduce more megakaryocyte.

A

Recombinant IL2

24
Q

Donor

A

lost of platelet containing blood product

25
Q

Recipient

A

May have alloantibodies directed against the antigens of blood products

26
Q

TTP- thrombotic thrombocytopenic purpura

A

Deficiency disintegrate + ADAMTS 13- gene that produces enzyme that controls vWF (uncontrolled very large)

27
Q

Disease TRIAD: MHA thrombocytopenia and neurologic abnormality Moschowitz syndrome

A

TTP- thrombotic thrombocytopenic purpura

28
Q

DIC- Disseminated intravascular coagulation

A

Plt are trapped in fibrin clotsbecause of simultaneous coagulation

29
Q

DIC- Disseminated intravascular coagulation

A

Acute onset with plt consumption, Factor V,VIII and fibrinogen reduced level
Life threatening

30
Q

-vWF involvement

A

HUS- Hemolytic uremic syndrome

31
Q
  • No apparent cause
  • Presence of anti-platelet AB (IgG)
  • Anti-plt antibodies destroys GpIIbIIIa
  • Remove to the circulation by the reticuloendothelial cells
A

ITP - idiopathic thrombocytopenic purpura renamed to immune TP

32
Q

HIT- Heparin Induced thrombocytopenia

A
  • Develops IgG antibody specific for heparin plt factor 4 complex
  • Due to unfractioned heparin administration
  • Heparin helps plt factor IV for aggregation
33
Q

Acute: 1-3 weeks infection from mumps, chicken pox, measles (viral infection) Ag binds to AB = immune complex- plt GpIIBIIIa abrupt onset, usually on children.

A

Characterized by bruising, petechiae and epistaxis

34
Q

Chronic: any age onset

A

Characterized by: menorrhagia, epistaxis and bruising

35
Q

Splenic sequestration

A
  • ⅓ of plt sequestered on spleen
36
Q

true thrombocytosis
- Has unregulated plt production and has variable size
- More than 450,000/uL
- Hallmark of myeloproliferative disorders : polycythemia Vera, chronic myelofibrosis. (Can exceed 1M/uL or go as High as 2M/uL
- Essential thrombocythemia

A

Primary thrombocytosis

37
Q

true thrombocytosis
- Has unregulated plt production and has variable size
- More than 450,000/uL
- Hallmark of myeloproliferative disorders : polycythemia Vera, chronic myelofibrosis. (Can exceed 1M/uL or go as High as 2M/uL
- Essential thrombocythemia

A

Primary thrombocytosis

38
Q

Compensate the loss plt due to trauma
- Does not exceed 800,000/uL
- Secondary to inflammation and trauma (childbirth, splenectomy,IDA)
- Betterment of body
- Normal plt morphology
- Variable sizes
- Plt function normally because they could respond to normal stimuli or regulatory stimuli.

A

Secondary/ Reactive thrombocytosis